SERES THERAPEUTICS, INC. (NASDAQ:MCRB) Files An 8-K Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition.
On March6, 2019, Seres Therapeutics, Inc. (the Company) announced its financial results for the year and quarter ended December31, 2018 and provided operational updates. The full text of the press release issued in connection with the announcement is furnished as Exhibit99.1 to this Current Report on Form8-K.
The information in this Item 2.02 of this Form8-K (including Exhibit99.1) shall not be deemed filed for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly provided by specific reference in such a filing.
Item 2.02. Financial Statements and Exhibits.
The following exhibit relates to Item 2.02, which shall be deemed to be furnished, and not filed:
| Press Release issued on March6, 2019 |
Seres Therapeutics, Inc. Exhibit
EX-99.1 2 d715880dex991.htm EX-99.1 EX-99.1 EXHIBIT 99.1 Seres Therapeutics Reports Fourth Quarter and Full Year Financial Results and Provides Operational Updates – Initiated SER-287 Phase 2b study in mild-to-moderate ulcerative colitis – – Initiated SER-401 Phase 1b study in metastatic melanoma – – Conference call at 8:30 a.m. ET today – CAMBRIDGE,…
To view the full exhibit click here
About SERES THERAPEUTICS, INC. (NASDAQ:MCRB)
Seres Therapeutics, Inc. is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. SER-109 is its lead product candidate, which is designed to prevent further recurrences of Clostridium difficile infection (CDI). The Company is developing additional product candidates, including SER-262 to prevent an initial recurrence of primary CDI, SER-287 to treat inflammatory bowel disease (IBD), including ulcerative colitis, and SER-155 to treat enteric bacterial pathogens. The Company is also conducting research on metabolic diseases, such as early-stage, non-insulin dependent diabetes; obesity and metabolic syndrome; other inflammatory diseases; cancer chemotherapy and immune suppression, and rare genetic diseases.
